Sharetreck – Tracking Genomic Investments & clinical trials for HIV.

August 8, 2024
By Raj

Caribou Biosciences, a leading clinical-stage CRISPR genome-editing biopharmaceutical company, recently announced its financial results for the second quarter of 2024. The company also provided significant updates on its clinical programs, highlighting its commitment to advancing innovative therapies for hematologic malignancies and autoimmune diseases.

Financial Snapshot

As of June 30, 2024, Caribou Biosciences reported $311.8 million in cash, cash equivalents, and marketable securities. This financial cushion is expected to support the company’s operations into the second half of 2026, reflecting a six-month extension of their previous guidance. The extension was achieved through strategic cost containment measures, including a reduction in workforce and the discontinuation of certain preclinical programs.

Revenue for the quarter was $3.5 million, slightly down from $3.8 million in the same period last year. The decline was primarily due to the termination of a collaboration agreement with AbbVie, partially offset by revenue from a new agreement with Pfizer. On the expense side, research and development (R&D) costs rose to $35.5 million, driven by the ongoing clinical trials for their leading pipeline candidates. General and administrative expenses also increased slightly to $11.5 million, reflecting higher personnel costs.

Despite these investments, Caribou reported a net loss of $37.7 million for Q2 2024, compared to $29.5 million in Q2 2023.

Clinical Progress: Key Highlights

Caribou’s robust clinical pipeline is the centerpiece of their strategy, with four programs currently in clinical development:

1. CB-010 (ANTLER Phase 1 Trial):
   • CB-010 is an allogeneic anti-CD19 CAR-T cell therapy being tested for B cell non-Hodgkin lymphoma (B-NHL). Data presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting showed promising results. The company is now enrolling patients in a dose expansion cohort to further evaluate the therapy’s efficacy, particularly with a novel partial human leukocyte antigen (HLA) matching strategy. This approach aims to improve patient outcomes by enhancing CAR-T cell expansion and persistence.
2. CB-010 (GALLOP Phase 1 Trial):
   • Caribou is also preparing to initiate a Phase 1 trial of CB-010 in lupus nephritis and extrarenal lupus by the end of 2024. This trial will explore the potential of CB-010 to treat autoimmune diseases, incorporating the same partial HLA matching strategy used in their B-NHL trial.
3. CB-011 (CaMMouflage Phase 1 Trial):
   • CB-011 targets multiple myeloma and is currently in the dose escalation phase of its trial. Initial data from this trial is expected by the end of 2024.
4. CB-012 (AMpLify Phase 1 Trial):
   • This therapy is aimed at treating acute myeloid leukemia (AML). The trial has progressed to its second dose level, with enrollment ongoing.

Strategic Updates

In a move to streamline operations and focus resources on key programs, Caribou has discontinued its preclinical research into allogeneic CAR-NK therapies and reduced its workforce by approximately 12%. This decision, along with other cost-saving measures, has extended their cash runway by at least six months.

Additionally, the company appointed Dr. Terri Laufer, an expert in autoimmune diseases, to its scientific advisory board. Her expertise will be invaluable as Caribou advances its autoimmune disease programs, particularly the upcoming GALLOP trial.

Looking Ahead

Caribou has a busy year ahead with several critical milestones on the horizon:

• Q4 2024: Initial data from the CaMMouflage Phase 1 trial for CB-011 in multiple myeloma.
• H1 2025: Data from the expanded cohorts in the ANTLER Phase 1 trial for CB-010, focusing on second-line large B cell lymphoma (2L LBCL) and prior CD19 relapsed patients.
• H2 2025: Potential initiation of a pivotal Phase 3 trial for CB-010, contingent on successful outcomes from the ongoing trials.

Conclusion

Caribou Biosciences is making significant strides in advancing its clinical programs, with a clear focus on leveraging CRISPR genome-editing technology to address unmet needs in hematologic malignancies and autoimmune diseases. The company’s strong cash position, extended runway, and strategic focus on high-potential therapies position it well for future success. I think the partial HLA concept is a bonus. Investors and stakeholders should keep an eye on the upcoming data readouts and regulatory milestones that could shape the company’s trajectory in the coming years.